Clinical-stage biotech Poseida Therapeutics Inc. received a boost Monday from a $142 million series C financing, most of which comes from Novartis AG. The funding goes toward Poseida's lead product, P-BCMA-101, which is enrolling patients for a phase II registrational trial.